Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A melanoma that affects the central nervous system. It is characterized by pleomorphism, melanin pigmentation, a high mitotic rate, necrosis, and hemorrhage. It is a highly aggressive and radioresistant tumor. The prognosis is usually poor.
Biomarker and diagnostic research for primary melanoma of the central nervous system has been reported in the published literature.
1 clinical trial registered. Interventions under study include procedural interventions and biologic therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
85 publications have been identified in PubMed for primary melanoma of the central nervous system. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (15%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 30 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 13 | 15% |
Clinical study results | 11 | 13% |
Laboratory research | 11 | 13% |
Disease patterns and progression | 9 | 11% |
New treatment approaches | 6 | 7% |
Testing and diagnosis research | 4 | 5% |
Other research | 1 | 1% |
Soni A (2026). [PMID: 41574906](https://pubmed.ncbi.nlm.nih.gov/41574906/). *Int J Surg Pathol*. [Case Report / Case Series]
Palkovsky M (2026). [PMID: 42131458](https://pubmed.ncbi.nlm.nih.gov/42131458/). *Rep Pract Oncol Radiother*. [Clinical Trial Publication]
Aboelatta MA (2026). [PMID: 42053986](https://pubmed.ncbi.nlm.nih.gov/42053986/). *Melanoma Res*. [Diagnostic / Biomarker]
de la Fuente MI (2026). [PMID: 41191923](https://pubmed.ncbi.nlm.nih.gov/41191923/). *Neuro-oncology*. [Case Report / Case Series]
Slørdahl KS (2026). [PMID: 41664938](https://pubmed.ncbi.nlm.nih.gov/41664938/). *Acta oncologica (Stockholm, Sweden)*. [Clinical Trial Publication]
Glogowska A (2026). [PMID: 41683974](https://pubmed.ncbi.nlm.nih.gov/41683974/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Hanus E (2026). [PMID: 42005102](https://pubmed.ncbi.nlm.nih.gov/42005102/). *Cureus*. [Case Report / Case Series]
Piha-Paul SA (2026). [PMID: 41604813](https://pubmed.ncbi.nlm.nih.gov/41604813/). *ESMO open*. [Clinical Trial Publication]
Kelbert J (2026). [PMID: 41352132](https://pubmed.ncbi.nlm.nih.gov/41352132/). *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. [Gene Therapy / Novel Therapeutics]
Gallia GL (2026). [PMID: 42281575](https://pubmed.ncbi.nlm.nih.gov/42281575/). *Neurooncol Adv*. [Case Report / Case Series]